Urinary schistosomiasis

Summary

Urinary schistosomiasis (MONDO:0006001) is a disease and 4 clinical trials. Top therapeutic interventions include mefloquine, myrrh, and (s,r)-mefloquine. A subtype of urinary bladder disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urinary schistosomiasis
Mondo ID	MONDO:0006001
EFO	EFO:0007530
MeSH	D012553
DOID	DOID:1394
ICD-10-CM	B65.0
NCIT	C39294
SNOMED CT	236706006
UMLS	C1704430
MedGen	312392
GARD	0024269
Anatomy (UBERON)	UBERON:0001255
Is cancer (heuristic)	no

Also known as: Schistosoma haematobium (& vesical schistosomiasis) · Schistosoma hematobium infection · schistosomiasis due to Schistosoma haematobium · urinary bladder schistosomiasis

Disease family

This is a subtype of urinary bladder disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary schistosomiasis

Related subtypes (16): low compliance bladder, detrusor sphincter dyssynergia, female stress incontinence, urinary bladder tuberculosis, urinary bladder neoplasm, vesicoureteral reflux, cystitis, overactive bladder, bladder calculus, bladder neck obstruction, postcholecystectomy syndrome, ureterolithiasis, bladder diverticulum, ureterocele, Hinman syndrome, disorder of neck of urinary bladder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Artesunate	Phase 3 (in late-stage trials)
Mefloquine	Phase 3 (in late-stage trials)
Praziquantel	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Artemether, Lumefantrine, Pyronaridine.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00870649	PHASE3	COMPLETED	Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium
NCT01529710	PHASE3	COMPLETED	Safety and Efficacy of Mirazid for Schistosomiasis Treatment
NCT01132248	PHASE2	COMPLETED	Activity of Mefloquine Against Urinary Schistosomiasis
NCT01512277	PHASE1	COMPLETED	Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MEFLOQUINE	4	1
MYRRH	3	1
(S,R)-MEFLOQUINE	0	1